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Background: A negative sentinel lymph node biopsy (SLNB) from patients with head and neck Merkel cell carci-
noma (HNMCC) may allow the patient to avoid further adjunctive therapies. However, there is considerable re-
gional variability of lymphatic drainage from primary sites involving the head and neck, and Merkel cell
carcinoma (MCC) has aggressive biologic behavior.
Objective: The primary aim of this systematic review was to document the incidence of regional recurrence and
mortality from HNMCC patients after a negative SLNB.
Methods: A systematic search of the English literature was conducted via Ovid Medline and Embase from incep-
tion until 2013 and the Cochrane Central Register of Controlled Trials from 1991 to January 2014.
Results: Twenty-three studies, with a total of 81 patients matched the inclusion criteria. The incidence of regional
recurrence from the entire cohortwas 12.3%, and therewas a 5%mortality rate. Themean follow-up time, exclud-
ing the 30 patients who did not have individual follow-up times speciﬁed, was 32.8 months.
Limitations: This review included studies had variable follow-up durations and treatments for MCC.
Conclusions: Despite negative pathologic staging of the neck using SLNB in HNMCC patients, there is still a high
incidence of regional recurrence and mortality, over a short follow-up period.
© 2015 The Authors. Published by Elsevier Inc. on behalf of Women's Dermatologic Society. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Merkel cell carcinoma (MCC) is a rare aggressive neuroendocrine
neoplasm that occurs most commonly in the head and neck region
(Smith et al., 2012). It shows a high propensity for locoregional and
distant metastases (Bichakjian et al., 2007) and has a poor 5-year
survival rate ranging between 30% and 64% (Allen et al., 2005;
Bichakjian et al., 2007). MCC was recently discovered to be associated
with Merkel cell polyomavirus (Feng et al., 2008) and tends to present
in older patients with suppressed immune systems (Agelli et al.,
2010). To determine the appropriate therapy for the regional lymph
node basin, staging is required. This can take place clinically via clinical
examination and imaging and pathologically with the use of a sentinel
lymph node biopsy (SLNB), ﬁne-needle aspiration cytology, or regional
lymph node clearance.
SLNB started to becomewidely used in the staging and treatment of
MCC during the 1990s (Rodrigues et al., 2001; Santamaria-Barria et al.,
2013), although the ﬁrst trials of this technique may have been per-
formed even earlier (Messina et al., 1997). SLNB involves selecting, sur-
gically dissecting, and pathologically analyzing the lymph nodes that.
n behalf ofWomen's Dermatologic Soare ﬁrst drained from the primary tumor site. This method can be
used to predict whether further adjunctive therapy in the form of a re-
gional lymph node clearance or regional radiotherapy is warranted.
SLNB may promote quality of life for the patient by minimizing the
need for these further interventions at that particular time point, should
there be no metastatic disease identiﬁed in the sentinel nodes.
With regard to patients with non-site-speciﬁc MCC, data on the dif-
ferences in recurrence rates between negative and positive SLNB groups
are conﬂicting. Two meta-analyses have shown higher recurrence rates
(location of recurrence not speciﬁed) in patients with positive SLNB
(18.7−33%) compared with patients with negative SLNB (3–7.5%)
(Mehrany et al., 2002; Warner et al., 2008). However a large single
study by Fields et al. (2011) showed comparable nodal recurrence
rates between the positive (2.2%) and negative (8%) SLNB groups.
It is hard to compare rates of recurrence between positive and neg-
ative SLNB groups of patients, given that the treatments to the regional
lymph nodes that they typically receive are much different.
Normally, patients with negative SLNB do not undergo further sur-
gery to the regional lymph nodes to allow comparison with radiothera-
py. However, MCC is known to be a radiosensitive tumor, and a French
randomized control trial published in 2012 showed that regional radio-
therapy signiﬁcantly reduced regional recurrence rates compared with
the observation arm (p = .007) in a group of patients with clinically
negative nodes (Jouary et al., 2012).ciety. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
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and had a complete lymph node dissection (CLND) with or without
nodal radiotherapy (n = 21) and those who had nodal radiotherapy
alone (n = 17), there was only one nodal recurrence in the combined
group, occurring in a patient who had a CLND without radiotherapy
(Fields et al., 2011). This information supports the efﬁcacy of radiother-
apy for MCC and suggests that it may be as efﬁcacious as CLND (Fields
et al., 2011).
One of the main problems of SLNB in the head and neck region has
been the variation in lymphatic drainage patterns, which make it difﬁ-
cult to reliably predict the sentinel lymph node (Hoetzenecker et al.,
2011; Stadelmann et al., 2004; Willis and Ridge, 2007). The 2013
American National Comprehensive Cancer Network guidelines for the
treatment of MCC advise performing an SLNB for lymph nodes that
are disease free clinically (cN0) (National Comprehensive Cancer Net-
work, 2013). However, these guidelines also advise that SLNB is not
mandatory for the head and neck region, given that SLNB is less reliable
from this region (National Comprehensive Cancer Network, 2013).
There is little research documenting the value of SLNB in MCC of the
head and neck. This is important information for a number of reasons.
First, an SLNB may detect occult disease (Fields et al., 2011; Lok et al.,
2012). Second, an SLNB is complicated by the variation in lymphatic
drainage from the head and neck, which may cause false-negative re-
sults (Stadelmann et al., 2004;Willis and Ridge, 2007). Third, it has im-
plications for further treatment. A positive SLNB for metastasis means
that the patient will be offered further adjunctive therapies, including
lymph node dissection, radiation therapy, and potentially chemothera-
py (Fields et al., 2011; National Comprehensive Cancer Network, 2013).
However, a negative SLNB may result in the patient not being offered
adjunctive treatment to the regional lymph nodes (National Compre-
hensive Cancer Network, 2013), which could impair disease-free sur-
vival and overall survival rates (Clark et al., 2007; Veness et al., 2005)
and increase the risk of regional recurrence (Clark et al., 2007). Hence,
it is important to closely examine how patients with head and neck
MCC who have a negative SLNB biopsy are managed and what their
prognosis is.
The primary purpose of this paper was to conduct a systematic re-
view of the English literature to determine the regional recurrence
and mortality rates among patients with head and neck MCC who
have a negative SLNB. Second, the aim was to determine whether ad-
junctive radiotherapy to either the primary tumor site or the regional
lymphatic basin had any signiﬁcant inﬂuence on the regional recurrence
or mortality rates among patients with head and neck MCC who a neg-
ative SLNB.
Methods
A systematic literature search, limited to the English language, was
conducted by using Ovid Medline from 1946 until 2013, Embase search
through Embase and Medline records from 1966 until 2013, and the
Cochrane Central Register of Controlled Trials from 1991 to January
2014 (Fig. 1). Abstracts were ﬁltered for content, and original papers
that discussed MCC were selected for further perusal.
Inclusion criteria were as follows: studies with a minimum of two
patients; patients with MCC of the head and neck; patients with a neg-
ative SLNB; and information pertaining to the survival status or recur-
rence of MCC for each patient undergoing SLNB. Patients were
included if they had a follow-up period of 3 months or more. Studies
that did not specify individual follow-up periods but indicated an aver-
age or median follow-up of 3 months or more were also included.
Studies were excluded if no follow-up duration was speciﬁed and if
there were duplicated reports. From the studies that were included, pa-
tients who could be identiﬁed as having no follow-up duration speciﬁed
were also excluded. Single case reportswere excluded tominimizepoten-
tial bias of reporting. Cross-referencing from these papers was also con-
ducted to locate other relevant papers thatmatched the inclusion criteria.The following features were noted, if provided: gender, age, type of
surgery and local and regional radiotherapy provided at the time of di-
agnosis, time to recurrence, follow-up duration, location of recurrence,
and time to death if it occurred.
Two-tailed Fisher tests were conducted to determine if radiotherapy
to theprimary site or regional lymphatic basin in patientswith head and
neck MCC who had a negative SLNB signiﬁcantly inﬂuenced the inci-
dence of regional MCC recurrence. A signiﬁcant result was regarded as
a p value b .05. Missing or unknown data were excluded from analysis.
Statistical analyses were performed using GraphPad Software 2013.
Results
Twenty-three English language studies, containing 81 patients who
matched the inclusion criteria of the study, were identiﬁed (Tables 1
and 2). One study was excluded because it was unclear how long all
the patients in the group received follow-up (Wong et al., 2009). In
this study, there were 6 patients with head and neck MCC and a nega-
tive SLNB; of these patients, at least 1 experienced regional recurrence.
There were 3 patients in this study who had a recurrence documented
with a follow-up duration; however, no follow-up had been recorded
for patients who had no recurrence documented. The authors decided
to exclude all 6 patients from this study on the basis of selection bias
(if only the 3 patients with recurrence were to be included).
Two papers (Hill et al., 1999; Koljonen and Suominen, 2008) were
excluded as their data came from the same institute with overlapping
timeframes as two other larger papers that were included (Koljonen
et al., 2011; Lok et al., 2012). Patients in the studies from Shnayder
et al. (2008) and Civantos et al. (2006) came from the same institute;
however, reviewing individual patient data revealed one new patient
in the study by Civantos et al. (2006) who was not in the study by
Shnayder et al. (2008) Similarly, although the patients from the studies
by Schmalbach et al. (2005) and Su et al. (2002) came from the same in-
stitute, comparing the individual patient records showed that therewas
one patient from the Su et al. (2002) study who was not in the
Schmalbach et al. (2005) study, and therefore this patient was included
in this study.
Five papers of interest could not be accessed despite author corre-
spondence (Cirillo et al., 2003; Haeﬂiger et al., 2009; Li et al., 1997;
Pascone et al., 2003; Rosa deAlmeida, 2002). Cross-referencing did not re-
veal any further papers that matched the inclusion and exclusion criteria.
The average follow-up timewas 32.8 months (excluding 30 patients
who did not have individual follow-up durations speciﬁed). Of the four
studies that had median follow-up times, the minimum in the range
of follow-up durations was 1 month. Table 2 summarizes patient char-
acteristics, treatment modalities, and patient outcomes. Ten of the
81 (12.3%) SLNB-negative patients had regional (nodal) recurrence, in-
cluding 1 patient who also had a distant recurrence (i.e., outside of the
local tumor site and beyond the regional lymph nodes). Nine of these
10 patients who had regional recurrence did not receive regional radio-
therapy, and in the case of one patient, the report did not specify if the
patient received regional radiotherapy. Of the total number of SLNB-
negative patients, 2 (5%) had distant recurrence.
Seven patients from the entire cohort were documented to have re-
ceived radiotherapy to the regional lymph nodes as part of their original
treatment despite negative SLNB, and 55did not receive any regional ra-
diotherapy at the time of negative SLNB. It was unclear whether the re-
maining 19 patients received regional radiotherapy at time of original
treatment for their MCC. No regional recurrence was documented for
the 7 patients who received regional radiotherapy.
Of the surviving7patientswhohad regional or distant recurrence (see
Table 1 – patient reference numbers [PRN]: 2, 20, 34, 35, 48, 62, and 80),
all underwent further treatment. Six patients (see Table 1 – PRN 2, 20, 34,
35, 62, and 80) received regional salvage surgery and adjuvant radiother-
apy, and one patient (see Table 1 – PRN 48) received radiotherapy alone.
Four patients (see Table 1 - PRN 2, 20, 48, and 80)were disease free at 14,
Fig. 1. The literature search process.
43N.G. Maher, D.F. Murrell / International Journal of Women's Dermatology 1 (2015) 41–4630, 15, and 36 months’ follow-up, respectively. In two patients (see
Table 1 – PRN 34 and 35), the subsequent outcome was said to be “suc-
cessful.” It was unknown if PRN 62 (see Table 1) had further disease
recurrence.
PRN 28 (see Table 1) had recurrence to the supraclavicular region
and distantly to the liver and ultimately died as a result of metastatic
MCC. PRN 50 (see Table 1) had distant recurrence to the lungs detected
at 8 months and died as a result of disease at 18 months.
Two-tailed Fisher tests did not reveal any signiﬁcant correlation be-
tween regional recurrence and radiotherapy to the primary site (p =
.30) or the regional lymphatic basin (p= .58).
Discussion
The primary purpose of this paper was to conduct a systematic re-
view of the English literature to determine the regional recurrence
andmortality rates among patients with head and neckMCC and a neg-
ative SLNB. Second, the aimwas to determinewhether adjunctive radio-
therapy to either the primary tumor site or regional lymphatic basin had
any signiﬁcant inﬂuence on regional recurrence or mortality rates
among these patients.
This systematic review revealed a 12.3% incidence (10/81) of region-
alMCC recurrence fromprimary head andneckMCC that had a negative
SLNB. Regional recurrence occurred early, within the ﬁrst 20 months
following a negative SLNB. This is consistent with the aggressive biolog-
ic behavior of these tumors (Medina-Franco et al., 2001) and the ten-
dency for early recurrence within the ﬁrst 12 to 24 months (Allen
et al., 2005; Medina-Franco et al., 2001; Smith et al., 1995). There was
a 5% mortality rate (4/81) attributable to MCC from this study popula-
tion, including 3 patients with regional recurrent disease and 1 patient
with only distant recurrence, over an average follow-up duration of
32.8 months.
At least 8.6% of this study population received radiotherapy to the
regional lymphatic basin despite a negative SLNB. It was unclearwheth-
er 23% (19/81) of this patient cohort received regional radiotherapy. No
signiﬁcant correlation was found between radiotherapy (at the time of
negative SLNB) to the regional lymphatic basin and the incidence of re-
gional MCC recurrence. Despite this, no regional recurrence occurred in
the 7 patients who were documented to have received regionalradiotherapy, and 16% (9/55) of the patients documented to have re-
ceived no regional radiotherapy had regional recurrence. However,
the small size of the study population and incomplete treatment data
on some patients limits the extrapolation of these ﬁndings.
In comparison, a randomized open trial with 83 patients with MCC
who were clinically node negative, which was performed to determine
if regional radiation improved overall survival and reduced regional re-
currence, showed no signiﬁcant difference for overall survival (p =
.989) (Jouary et al., 2012). However, there was a statistically signiﬁcant
reduction in regional recurrence rates among those who received re-
gional radiotherapy (p= .007). The problem in these data is that with-
out SLNB, patients with undetected positive lymph nodes could have
been randomized to radiotherapy, and others with possibly negative
lymph nodes received no radiotherapy; therefore, even if radiotherapy
improved survival for the ﬁrst group, the survival difference could
have been masked, as the groups were not even at baseline. For that
study, the median follow-up time was 57.7 months (range 12.8–130),
and in 43.4% of the patient cohort, the primary MCC sites involved the
head and neck region. This trial was prematurely terminated when
the recruitment number dropped,whichwas attributed to the introduc-
tion of SLNB for managing MCC. As MCC is known to be a highly radio-
sensitive tumor (Hruby et al., 2013), it is necessary to further explore
what survival advantage regional radiation therapy may confer on neg-
ative SLNB patients.
In comparison with the mortality rates published in other reports,
our study population with negative SLNBs had a much lower disease-
speciﬁc mortality rate compared with another population of patients
with cN0 head and neck MCC who had not had SLNB (Gillenwater
et al., 2001). That study by Gillenwater et al. (2001) showed that there
was a disease-speciﬁcmortality rate of 43% (22/51) among cN0 patients
whohad had aminimum follow-up of 6months. In this group of cN0pa-
tients, 39% (20/51) had received multimodal treatment (surgery and
locoregional radiotherapy). The large difference in mortality rates be-
tween the present study and that by Gillenwater et al. (2001) suggests
that a negative SLNB from head and neck primary tumor sites may indi-
cate an improved survival outcome.
This suggestion is also supported by data from a large American
study on patients with head and neck MCC (n= 2104), which showed
that patients with pathologically proven negative lymph nodes have
Table 1
Patient characteristics, treatment modalities, and patient outcomes.
Patient (reference) Age/Gender Surgery primary XRT local XRT regional Regional Recurrence (months) Follow-up (months)
1 (Pan et al., 2002) 44 M WLE No No No A (25)
2 (Pan et al., 2002) 58 F WLE No No Yes (3) A (14)
3 (Su et al., 2002) 77 F WLE No No No A (19)
4 (Koljonen and Suominen, 2008) 72 F WLE Yes Yes No A (22)
5 (Alex, 2004) 83 F WLE Yes No No A (29)
6 (Alex, 2004) 77 F WLE No No No A (28)
7 (Alex, 2004) 88 F WLE No No No A (13)
8 (Alex, 2004) 90 M WLE NS NS No A (20)
9 (Alex, 2004) 82 F WLE No No No A (11)
10 (Koljonen et al., 2011) NS WLE NS NS No A (N10)
11 (Koljonen et al., 2011) NS WLE NS NS No A (N10)
12 (Koljonen et al., 2011) NS WLE NS NS No A (N10)
13 (Koljonen et al., 2011) NS ExcN NS NS No A (N10)
14 (Koljonen et al., 2011) NS ExcN NS NS Yes (NS) DOD (NS)
15 (Howle and Veness, 2012) 86 M NS NS No No DOC (4)
16 (Howle and Veness, 2012) 61 F NS NS No No A (34)
17 (Howle and Veness, 2012) 62 M NS NS No No A (5)
18 (Schmalbach et al., 2005) 84 F WLE No No No A (33)
19 (Schmalbach et al., 2005) 55 F WLE No No No A (31)
20 (Schmalbach et al., 2005) 74 M ExcB, WLE No No Yes (9) A (30)
21 (Schmalbach et al., 2005) 84 F WLE No No No A (28)
22 (Schmalbach et al., 2005) 83 F WLE No No No A (27)
23 (Schmalbach et al., 2005) 85 M WLE No No No A (58)
24 (Schmalbach et al., 2005) 71 F WLE No No No A (57)
25 (Schmalbach et al., 2005) 68 F WLE No No No A (12)
26 (Shnayder et al., 2008) NS WLE Yes Yes No A (13)
27 (Shnayder et al., 2008) NS WLE Yes Yes No A (45)
28 (Shnayder et al., 2008) NS WLE No No Yes (20)§ DOD (NS)
29 (Shnayder et al., 2008) NS WLE No No No A (12)
30 (Shnayder et al., 2008) NS WLE No No No A (40)
31 (Shnayder et al., 2008) NS WLE Yes Yes No A (15)
32 (Luaces et al., 2008) 55 F WLE No No No A (18)
33 (Luaces et al., 2008) 62 F WLE No No No A (9)
34 (Lok et al., 2012) NS NS NS No Yes (3, 2–5)⁎ NS (35, 1–220)⁎
35 (Lok et al., 2012) NS NS NS No Yes (3, 2–5)⁎ NS (35, 1–220)⁎
36 (Lok et al., 2012) NS NS NS NS No NS (35, 1–220)⁎
37 (Lok et al., 2012) NS NS NS NS No NS (35, 1–220)⁎
38 (Lok et al., 2012) NS NS NS NS No NS (35, 1–220)⁎
39 (Messina et al., 1997) NS WLE NS NS No A (10.5)†
40 (Messina et al., 1997) NS WLE NS NS No A (10.5)†
41 (Messina et al., 1997) NS WLE NS NS No A (10.5)†
42 (Messina et al., 1997) NS WLE NS NS No A (10.5)†
43 (Messina et al., 1997) NS WLE NS NS No A (10.5)†
44 (Zeitouni, 2000) 78 F Mohs Yes Yes No A (16)
45 (Wasserberg, 2000) 68 F WLE Yes No No A (8)
46 (Maza et al., 2006) 70 F WLE No No No A (66)
47 (Maza et al., 2006) 55 M WLE No No No A (69)
48 (Warner et al., 2008) 78 F WLE No No Yes (4) A (15)
49 (Warner et al., 2008) 69 F WLE Yes NS No A (16, 4–75)⁎
50 (Righi et al., 2013) 73 F NS NS No No (8)‡ DOD (11)
51 (Righi et al., 2013) 74 F NS NS No Yes (8) DOD (18)
52 (Righi et al., 2013) 90 M NS NS No No A (64)
53 (Righi et al., 2013) 72 F NS NS No No A (3)
54 (Righi et al., 2013) 81 F NS NS No No DOC (33)
55 (Righi et al., 2013) 67 M NS NS No No A (67)
56 (Righi et al., 2013) 81 F NS NS No No DOC (10)
57 (Righi et al., 2013) 85 F NS NS No No A (64)
58 (Righi et al., 2013) 66 M NS NS No No A (54)
59 (Righi et al., 2013) 74 F NS NS No No DOC (102)
60 (Maalouf et al., 2012) NS ExcN NS Yes No A (18.7, 14–26)⁎
61 (Maalouf et al., 2012) NS ExcN NS Yes No A (18.7, 14–26)⁎
62 (Maalouf et al., 2012) NS NS No No Yes (6) A (18.7, 14–26)⁎
63 (Maury et al., 2011) 85 F WLE Yes No No A (27.6)†
64 (Maury et al., 2011) 69 F WLE Yes No No A (27.6)†
65 (Maury et al., 2011) 59 F WLE Yes No No A (27.6)†
66 (Civantos et al., 2006) NS WLE NS NS No A (36)
67 (Morand et al., 2013) 52 F Exc No No No A (18)
68 (Morand et al., 2013) 64 M Exc Yes NS No A (72)
69 (Morand et al., 2013) 57 F Exc No No No A (66)
70 (Morand et al., 2013) 73 F Exc No No No A (74)
71 (Morand et al., 2013) 65 F Exc Yes NS No A (39)
72 (Parvathaneni et al., 2012) NS Exc No No No A (12, 4–45)⁎
73 (Parvathaneni et al., 2012) NS Exc No No No A (12, 4–45)⁎
74 (Parvathaneni et al., 2012) NS Exc No No No A (12, 4–45)⁎
75 (Parvathaneni et al., 2012) NS Exc No No No A (12, 4–45)⁎
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Table 1 (continued)
Patient (reference) Age/Gender Surgery primary XRT local XRT regional Regional Recurrence (months) Follow-up (months)
76 (Parvathaneni et al., 2012) NS Exc No No No A (12, 4–45)⁎
77 (Parvathaneni et al., 2012) NS Exc No No No A (12, 4–45)⁎
78 (Parvathaneni et al., 2012) NS Exc No No No A (12, 4–45)⁎
79 (Parvathaneni et al., 2012) NS Exc No No No A (12, 4–45)⁎
80 (Bleyen et al., 2010) 71 F Exc No No Yes (4) A (36)
81 (Hamill and Messina, 2010) 77 M WLE Yes NS No DOC (60)
WLE, wide local excision; ExcB, excisional biopsy; NS, non-speciﬁed; ExcN, excision narrow margin; Exc, excision, uncertain if wide margin; A, alive; DOD, died of disease; DOC, died of
other cause.
⁎ median time for study cohort, followed by range.
† mean time for study cohort, followed by range when available.
‡ distant recurrence.
§ regional and distant recurrence.
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have lymph nodes histologically examined (Smith et al., 2012). Despite
this, the same study also showed that disease-speciﬁc survival was not
different between negative (n = 133) and positive (n = 40) SLNBs
from patients with head and neck MCC (p = .14) (Smith et al., 2012).
One possible explanation may be that SLNB-positive patients receive
greater adjunctive treatment at the time of diagnosis compared with
SLNB-negative patients (Fields et al., 2011; Gupta et al., 2006). Other hy-
potheses with regard to the ﬁnding that there is no survival difference
between positive and negative SLNBs in head and neck MCC include
that the SLNBmissesmicrometastatic disease (false-negative rate), per-
haps as a result of the spread of Merkel cell polyomavirus, and that, as
discussed by Fields et al. (2011), SLNB may effectively treat
micrometastatic disease.
In terms of regional recurrence rates, this review showed a lower re-
gional recurrence rate of 12.3% (10/81), comparedwith other studies of
cN0 patients with head and neckMCCwhodid not have an SLNB,where
regional recurrence rates ranged between 20% and 53% (3/15 (Brissett
et al., 2002); 27/51 (Gillenwater et al., 2001)). This may be a result of
the differences between the groups in follow-up durations, treatment
modalities, and clinicopathologic features of the primary tumors or
the possibility that a negative SLNBmay help predict future regional re-
currence rates.
The incidence of regional recurrence in this review of the literature
(12.3%) were similar to regional recurrence rates (2.5-17.7%) from larg-
er studies (Fields et al., 2011; Tarantola et al., 2013) and ameta-analysisTable 2
Summary of the included patients from the systematic review.
Characteristic n (%)
Gender Female 36 (44)
Male 12 (15)
Not speciﬁed 33 (41)
Mean age (year) 72 (SD = 11.1, Range 44–90)
Surgery to primary site Wide local excision 43 (53)
Mohs 1 (1)
Excision, Margins unspeciﬁed 14 (17)
Excision, Narrow Margin 4 (5)
Not speciﬁed 19 (23)
Radiotherapy to primary site Yes 14 (17)
No 34 (42)
Not speciﬁed 33 (41)
Radiotherapy to regional lymphatics Yes 7 (9)
No 55 (68)
Not speciﬁed 19 (23)
Neck dissection as part of
initial treatment
Yes 0 (0)
No 69 (85)
Not speciﬁed 12 (15)
MCC recurrence (regional, distant) Yes 11 (14)
No 70 (86)
Death from MCC Yes 4 (5)
No 67 (83)
Not speciﬁed 10 (12)
SD, standard deviation; MCC, Merkel cell carcinoma.(Mehrany et al., 2002) of non-site-speciﬁcMCCwith a negative SLNB. In
two of these studies, itwas reported that 88% (Mehrany et al., 2002) and
92% (Fields et al., 2011) of patients with a negative SLNB received no
further treatment to the regional lymphatic basin. In the group of pa-
tients from this review, at least 68% of patients received no further sur-
gery or radiotherapy to the regional lymphatic basin. In their review of
the literature, which included 22 studies, Warner et al. (2008) showed
that there was a 7.5% incidence of recurrence following a negative
SLNB in a population of patients with non-site-speciﬁc MCC. However,
in this literature review, recurrence was not speciﬁed as regional
recurrence.
One of the strengths of our study was the speciﬁc citing of regional
recurrence outcomes and not locoregional recurrence outcomes. It is
important to differentiate between these two recurrences, as it is re-
gional recurrence that is the relevant outcomemeasure for SLNB studies
(Fields et al., 2011). To date, the largest study examining patients with
MCC of the head and neck, which featured 133 patients with a negative
SLNB taken from the Surveillance, Epidemiology and End Results pro-
gram of the National Cancer Institute in the United States in 2012, did
not report on recurrence rates (Smith et al., 2012).
Therewere several limitations to the present study: (1) The searches
were limited to the English language literature. (2) There was signiﬁca-
tion variation in follow-up durations in this cohort of patients. The
shorter follow-up duration in the case of some included patients did
not permit reliable disease-speciﬁc survival calculations from these
data, nor did it provide sufﬁcient time for regional or distant recurrence
to develop. Therefore, the incidence rates of mortality and recurrence in
this study are likely to be underestimates. (3) The pathologic analyses of
the sentinel lymph node may vary among institutes (Su et al., 2002).
Routine immunostaining for CK-20, in addition to hematoxylin and
eosin staining, increases the diagnostic reliability of ﬁnding lymph
nodes metastatically involved by MCC (Su et al., 2002). Future institu-
tional studies should aim to control for this variable. (4) The different
modalities of treatment received by patients present confounding vari-
ables that impair the evaluation of how a negative SLNB prognosticates
for recurrence or survival. This is also an issue when comparing recur-
rence and survival between negative and positive SLNBs. (5) No infor-
mation on primary tumor characteristics was included in the analysis.
This was the result of lack of information about the majority of patients
included in this study. (6) Lack of information pertaining to the nature
of treatment received by some patients, including improved immuno-
suppression, limited the ability to draw conclusions aboutwhat adjunc-
tive therapies following a negative SLNB may be most beneﬁcial.
In addition, several studies that were reviewed had a cohort of neg-
ative SLNBMCCpatients, from a variety of sites around the body, includ-
ing from the head and neck region. However, studies in which it was
impossible to determine the outcome that could be directly attributed
to the cohort of patients with head and neck MCC had to be excluded.
In summary, SLNB should become a routine part of the workup in
patients with head and neck MCC who are clinically staged as disease
free. SLNBs aid in the detection of occult disease and positive SLNBs pro-
vide clear indications for adjunctive treatment; however, a negative
46 N.G. Maher, D.F. Murrell / International Journal of Women's Dermatology 1 (2015) 41–46SLNB also provides important information. A negative SLNB in patients
with head and neck MCC is likely to indicate an improved disease-
speciﬁc survival and reduced risk of regional disease recurrence com-
pared with patients who are clinically staged as disease free and who
do not undergo further pathologic evaluation of the lymph nodes in the
head and neck region. However, close follow-up is still necessary for all
patients with head and neck MCC, including those with a negative SLNB.
This systematic review has indicated thatwhat adjunctive treatment
should be provided following a negative SLNB and surgery to the prima-
ry tumor in patients with head and neck MCC still remains unclear. To
determine the most appropriate treatment for these patients, it would
be ideal to perform a randomized controlled trial to determine the
need for regional radiotherapy. Given that even in the case of small tu-
mors (b0.5 cm), there is still a signiﬁcant risk for lymph nodemetastasis
(Iyer et al., 2014); such a study would help avoid stratiﬁcation of pa-
tients based on tumor size. Further case series studies with longer
follow-up durations beyond 2 years, comparing treatments provided
to patients with negative SLNBs from head and neck MCC primary
tumor sites, are another option to determine the best approach to
treating this uncommon tumor.
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